Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Unraveling the idiosyncratic

A key current safety concern is how to identify patients who might be at risk of rare but serious adverse events from drugs. Because these events are so rare, no single company can collect enough data to perform a meaningful statistical analysis based on the SAEs that occur with an individual drug. But many of these SAEs are triggered by different drugs. Last week, seven pharmaceutical companies teamed up with academic institutions and FDA to identify genetic markers that could predict which patients are at risk of drug-related adverse events.

If the consortium is successful, patients would get access to drugs that otherwise might not be on the market, drug companies would get more drugs to market and shut down fewer late-stage programs, and the healthcare system would save money

Read the full 1293 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE